SCHEMBL28360326

SCHEMBL28360326

CCCc1c(OCCCSc2ccc(C(C)=O)c(O)c2)ccc(C(C)=O)c1OCCCC(=O)O

nearest known ligand 0.70

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 16/20 0.70
CYSLTR1 Q9Y271 16/20 0.70
PPARG P37231 2/20 0.51
PPARD Q03181 2/20 0.51
PPARA Q07869 2/20 0.51
LTB4R Q15722 1/20 0.48
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
NFKB1 P19838 1/20 0.47
BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tipelukast SCHEMBL154898 0.85 CYSLTR2 (0.78) CYSLTR2CYSLTR1PPARGPPARDPPARA
Tipelukast SCHEMBL29359070 0.85 CYSLTR2 (0.78) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL9734038 0.83 CYSLTR2 (0.62) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL21894565 0.82 CYSLTR2 (0.61) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL9623054 0.82 CYSLTR2 (0.98) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL9622269 0.82 CYSLTR2 (1.00) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL10688316 0.82 CYSLTR2 (1.00) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL9622368 0.82 CYSLTR2 (0.96) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL9435407 0.82 CYSLTR2 (0.79) CYSLTR2CYSLTR1PPARGPPARDPPARA
SCHEMBL10691639 0.82 CYSLTR2 (0.86) CYSLTR2CYSLTR1PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110840847-B Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases 沃泰克斯药物股份有限公司 2022-07-29 CN disclosed
CN-106163517-B Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases 沃泰克斯药物股份有限公司 2020-08-14 CN disclosed
CN-110840847-A Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases 沃泰克斯药物股份有限公司 2020-02-28 CN disclosed